Enhe Technology
恩和科技
Enhe Biotechnology (恩和生物, also known as Bota Bio or Bota Biosciences) is a global industrial synthetic biology company founded by CEO 崔好 (Cheryl Cui), an MIT PhD . In July 2021, it raised over $100 million in a Series B round led by Sequoia China (红杉中国), with participation from Zhaoyin International Capital and existing investors including Matrix Partners China, Sherpa Healthcare Partners, Source Code Capital, and 5Y Capital (五源资本) . By early 2024, the company had approximately 200 employees and had formally launched its industrialization process in 2023, according to 崔好 in a 5Y Capital interview . The company was also named to *China Entrepreneur* magazine's 2023 "Rising 100" list of high-growth innovative companies .
AI-generated — may contain errors, please verify.
Coverage
Is the "ChatGPT Moment" for Bio-Manufacturing Here? | 5Y Talk
From the industry's ups and downs to the inflection point brought by AI, from a "lab crayfish" to the "ChatGPT moment" of bio-manufacturing.
五源资本·In the Biological World, a Foothold for Physical AI
"In the seven years since Enhe was founded, how has an industrial technology company grown AI capabilities?"
暗涌Waves·
